







Financial Data Highlights





Sales revenue increased by ¥159.4 billion compared to the previous fiscal year, driven by increased pesticide shipments, primarily in South America, within the Agro & Life Solutions Sector, as well as by increased sales of Sumitomo Pharma's three key products. Core operating income improved by ¥289.6 billion compared to the previous fiscal year. This was due to business divestitures under the immediate-term, concentrated measures to improve business performance, increased sales of Sumitomo Pharma's three key products, and reduced fixed costs.





Net income attributable to owners of the parent improved by ¥350.4 billion compared to the previous fiscal year, reaching ¥38.6 billion. This was driven by a significant improvement in core operating income and a substantial decrease in impairment losses.





Cash flows from operating activities increased by ¥284.3 billion due to a significant improvement in pre-tax income. Cash flows from investing activities improved by ¥197.5 billion to ¥85.2 billion due to increased proceeds from the sale of cross-shareholdings and business divestitures. As a result, free cash flow improved by ¥481.8 billion to ¥318.3 billion.



Due to the significant improvement in net income attributable to owners of the parent, both ROE (Return on Equity) and ROIC (Return on Invested Capital) recovered significantly from the previous fiscal year.





Total assets decreased by ¥495.0 billion compared to the previous fiscal year, reaching ¥3,439.8 billion. This was primarily due to the sale of cross-shareholdings and other assets as part of immediate-term, concentrated measures to improve business performance, as well as reductions in inventories and the write-off of loans to Petro Rabigh.





By allocating cash generated through immediate-term, concentrated measures to improve business performance to repay interest-bearing liabilities, the outstanding balance of interest-bearing liabilities decreased by ¥277.4 billion compared to the previous fiscal year.

*1 D/E Ratio=Interest-bearing liabilities/Total equity
*2 Net D/E Ratio=Net interest-bearing liabilities (Interest-bearing liabilities-Cash and cash equivalents)/Equity attributable to owners of the parent



For FY2024, the annual dividend per share was set at 9 yen per share. The dividend payout ratio was 38.2%.

(Note) The dividend payout ratio has not been calculated for FY2023, as we recorded a net loss during this period.



R&D expenses decreased by ¥38.8 billion compared to the previous fiscal year, amounting to ¥145.2 billion. This was primarily due to advancing the selection and concentration of R&D investments at Sumitomo Pharma.